Nicholas DeNittis

Nick DeNittis writes and edits AI industry trends and use-cases for Emerj's editorial and client content. Nick holds an MS in Management from Troy University and has earned several professional analytics certificates, including from the Wharton School.

Articles by Nicholas

14 articles
Emerj.com – 001 – AI at ExxonMobil-min

Artificial Intelligence at ExxonMobil – Two Applications at the Largest Western Oil Company

ExxonMobil is the largest investor-owned company in the world and the largest oil company in the Western world. It is headquartered in Irving, Texas.

Personalizing Product Recommendations 
at Walmart@2x-min

Personalizing Product Recommendations at Walmart – with Dr. Charles Martin

The en masse shift to online shopping that transpired during and post-COVID appears as if it's destined to last. According to the Brookings Institute, one third of US adults have used delivery apps to order from a restaurant or store in the last year. 

What Enterprises Can Learn from How Google Models AI Readiness@2x-min

What Enterprises Can Learn from How Google Models AI Readiness – with Pallab Deb of Google Cloud

It is exceptionally difficult to get started, much less succeed, in AI adoption if one does not have at least a foundational education, particularly in those “modules” pertaining to AI capabilities, requirements, and organizational readiness. A business wanting to implement AI must understand the current state of adoption and how this current state matches up against AI readiness requirements.

What AI Means for Financial Services in a Post-COVID World@2x-min

Early AI Adoption: How to Avoid Classic Mistakes – With David Carmona of Microsoft

The main difficulty in starting with AI is knowing exactly where to begin. As we will elaborate in this article, there are many exaggerated and misleading claims about the various types of AI technology. Moreover, some executives are too trigger-happy, wanting or needing to integrate AI into their enterprise sans a foundational education or understanding of the challenges. 

Building an AI Strategy Step-by-Step@2x

Building an AI Strategy, Step-by-Step – with Dr. Shane Zabel of Raytheon

What does developing an AI strategy look like? Most executives openly embrace the technology and the automation possibilities within their organization. They may just need a bit of help getting started.

What GPT-3 and AI Generated Text Means for the Future of Written Content@2x

What GPT-3 and AI-Generated Text Means for the Future of Written Content – with Peter Welinder of OpenAI

It is not hyperbolic to state that the autoregressive language model known as GPT-3 (short for ‘Generative Pre-trained Transformer 3’) is an unparalleled evolutionary step in content creation. In fact, the potential outputs the model can produce are so advanced that many academics have cited GPT-3 as Exhibit A in calling universities to reconsider what constitutes academic plagiarism. 

Using Decision Augmentation for Client Retention@2x

Using Decision Augmentation for Client Retention – with Emily Bremner of Signal AI

Actionable, decision-augmenting data can be obtained internally or externally. Of course, external data is a far richer and more diverse source, as it comprises every other piece of digital information outside of the four walls of an enterprise. 

Artificial Intelligence 
at Twitter@2x

Artificial Intelligence at Twitter – Two Current Use Cases

Twitter is an American communications company based in San Francisco, California, best known for the microblogging and social networking site of the same name. As of January 2022, the company had over 229 million daily active users.

Artificial Intelligence at Chevron 950×540

Artificial Intelligence at Chevron

Chevron is the second largest producer of oil in the United States (Exxon Mobil). The company is traded on the NYSE (symbol: CVX) and has a market capitalization of approximately $322 billion.  

Clinical Reporting 
and Drug Discovery@2x

Clinical Reporting and Drug Discovery: An Overview of AI’s Impact in the Pandemic

The importance of AI in the pharmaceutical space has grown exponentially over the last few years, spearheaded by global demand for a COVID vaccine at the pandemic’s apex. Moreover, AI has proven helpful throughout the pandemic, all while providing glimpses into the future promise of the technology. 

subscribe-image
Stay Ahead of the Machine Learning Curve

Join over 20,000 AI-focused business leaders and receive our latest AI research and trends delivered weekly.

Thanks for subscribing to the Emerj "AI Advantage" newsletter, check your email inbox for confirmation.